Stay updated on REGN4336 in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the REGN4336 in Prostate Cancer Clinical Trial page.

Latest updates to the REGN4336 in Prostate Cancer Clinical Trial page
- Check6 days agoChange DetectedA new revision tag, v3.5.5, is added to the history and the previous v3.5.4 tag is removed. This updates the page's revision history.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedA new revision entry v3.5.4 was added to the history while the previous revision v3.5.3 was removed, indicating an update to the page itself rather than changes to the trial data.SummaryDifference0.1%

- Check34 days agoChange DetectedThe study title was updated to state REGN4336 is safe and works alone and in combination with REGN5678, removing Cemiplimab from the combination; the record history also adds several sections (IPDSharing, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Conditions, Study Description, Study Status, and Study Identification) to provide a more complete data representation.SummaryDifference1%

- Check49 days agoChange DetectedThis update reflects a revision/version bump on the ClinicalTrials.gov page interface (from v3.5.2 to v3.5.3), without indicating any changes to the study record details shown in the record history.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision v3.5.2 was added to the record history and Revision v3.5.0 was removed.SummaryDifference0.1%

- Check85 days agoChange DetectedThe record history adds a new revision entry v3.5.0. The prior revision v3.4.3 is removed.SummaryDifference0.1%

Stay in the know with updates to REGN4336 in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REGN4336 in Prostate Cancer Clinical Trial page.